Q2
BTSG — Q2 2026 Financial Report Analysis
BrightSpring's Q2 2026 revenue rose 23.0% to $3.87B and Adjusted EBITDA 44.2% to $205.5M, driven by specialty-drug pricing and mix (prescription volume was flat) and the Amedisys home-health branches; full-year guidance was raised again.